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Nuclear inositides are independently regulated and their regulation is completely independent from the plasma 
membrane correspondent, hinting that the nucleus represents a specialized distinct compartment of inositol 
lipids metabolism. This points out that nuclear inositol lipids themselves can influence nuclear key events as 
transcription and pre-mRNA splicing, growth, proliferation, cell cycle regulation and differentiation. 
Phospholipase C β1 (PLCβ1) is the most significant enzyme for nuclear inositide signaling. Very recently it has 
been highlighted that the role of PLCβ1 during erythropoiesis is linked to that of miR-210. Moreover, PLCβ1 
signaling is linked to gene regulation and changes in microRNAs (miRNAs) occur with PLCβ1 expression. 
Molecular targets of PLCβ1 have been found to be important during myogenesis and hematopoiesis. In addition, 
PLCβ1 signaling has been demonstrated to be impaired in diseases affecting both myogenic differentiation and 
affecting the hematopoietic system. 
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Introduction 
The roles of phosphoinositide-specific phospholipase C 
(PLC) have been extensively investigated in diverse cell lines 
and pathological conditions. It is clear today that lipid 
signaling molecules take part of the highly complex process 
that allows one extracellular signal to be transduced inside 
the cell, to the nucleus. In the nucleus, lipid signaling induces 
reactions that modulate the regulation of gene transcription, 
DNA replication or repair, and DNA cleavage, finally 
stemming in cellular differentiation, proliferation, apoptosis, 
or several other cellular functions 
[1-4]
. PLCβ1 catalyzes the
hydrolysis of the signaling lipid phosphatidylinositol 4, 
5-bisphosphate (PI-4,5P2) to produce the second messengers 
inositol 1, 5, -trisphosphate (IP3) and diacylglycerol (DAG). 
In general, PLCβ1 is activated by G-protein coupled receptor 
(GPCR) through several mechanisms at the plasma 
membrane whilst in the nucleus its activation depends on 
MAP kinase 
[5]
. In fact, the nucleus has a phosphoinositol
lipid signaling pathway that is independent of the one found 
on the plasma membrane and PLCβ1 is the major PLC in the 
nucleus. The function of PLCβ1 in the nucleus still remains 
an intriguing question even if it has been studied in great 
detail up to now. Other independent laboratories has 
thoroughly demonstrated that the phosphoinositide cycle and 
its related correspondent is also present in the nucleus, and 
may be relevant for several nuclear events such as mRNA 
export, DNA repair and gene transcription 
[6-9]
. Recent
evidences have revealed the importance of investigating the 
nuclear protein network behind PLCβ1 role and identifying 
the associated protein targets, thus giving more 
enlightenment into the interactors and downstream molecular 
effectors that even further elucidate its nuclear signaling 
cascade. PLCβ1 gene is present as alternatively spliced 
variants β1a and β1b, which differ in their C-terminal 
residues 
[10]
. PLCβ1a seemed to be localized preferentially in
the cytosol, but PLCβ1b was found mainly in the nuclei 
[11]
.
The subcellular localization denote a different physiological 
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role for PLCβ1, in normal cell proliferation or differentiation 
[12,13]
, which could result in a different role in pathogenesis. 
Here we review the emerging role of PLCβ1 in physiology 
and disease highlighting the importance of understanding the 
network behind PLCβ1 function and downstream target 
effectors. In this review we will confine our focus to the 
nuclear PLCβ1 and in particular, we will review the most 
updated literature on PLCβ1. 
Outline of PLCβ1 targets and pathology 
Skeletal muscle differentiation is characterized by 
terminal withdrawal from cell cycle, activation of 
muscle-specific genes and morphological changes, including 
myoblast alignment, elongation and fusion of mononucleated 
myotubes. Nuclear PLCβ1 is a key player in myoblast 
differentiation, and functions as a positive regulator of this 
process. Interestingly, it has been demonstrated that the 
differentiation of C2C12 mouse myoblasts in response to 
insulin stimulation is characterized by a marked increase in 
nuclear PLCβ1, which then appears to be a key player in the 
skeletal muscle differentiation program, by targeting cyclin 
D3 
[14,15]
. Cyclin D3 expression plays a critical role in the 
Myo-D-mediated arrest of the cell cycle, which precedes 
myoblast differentiation. In C2C12, PLCβ1 resides 
predominantly in the nucleus and activates cyclin D3 
promoter during the differentiation of myoblasts to 
myotubes, indicating that its function and nuclear 
localization are crucial regulator of the mouse cyclin D3 gene 
and that PLC signaling induced by insulin activates at least a 
lipid-dependent signaling pathways. Cyclin D3 gene 
expression is regulated by PLCβ1 induction of the cyclin D3 
promoter via the activation of the c-jun/AP1 transcription 
factor  
[16]
. In fact, C2C12 cell fusion into myotubes is 
significantly inhibited by the knockdown of both PLCβ1 
which is necessary for efficient muscle differentiation. 
Moreover, cyclin D3 promoter activation is under the control 
of molecular events that depend not only on 
PLCβ1expression levels and activity, but also on the nuclear 
localization of PLCβ1, because the over-expression of a 
PLCβ1 mutant for the nuclear localization sequence, which 
localizes only in the cytoplasm, inhibits both the promoter 
activity and the induction of differentiation 
[13]
. Nuclear 
PLCβ1signalling has been demonstrated to be involved in 
diseases showing an altered myogenic differentiation. These 
findings, obtained mostly by in vitro studies, resulted to have 
a great impact in pathophysiology, as the deregulation 
PLCβ1/cyclin D3 signaling has been associated also with 
myogenic diseases 
[17]
. Moreover, while cyclin D3 and cdk4 
are elevated in normal myotubes, Myotonic dystrophy 1 
(DM1) differentiating cells do not increase these proteins 
[18]
. 
Myotonic dystrophy (DM) is a myogenic disease 
characterized by an impaired myogenic differentiation and is 
the most prevalent form of muscular dystrophy in adults. At 
the onset, DM can appear as DM type 1 (DM1) or type 2 
(DM2), both dominantly inherited multisystem disorders. We 
know today that DM is not elicited by the presence of a 
mutated protein. Conversely, DM is the first acknowledged 
case of an RNA-mediated disorder. The presence of the 
mutated gene produces an expanded repeat RNA that is 
highly noxious to cells. The mutant RNA is accumulated in 
the nucleus compartment, originating ribonuclear clusters in 
pathological tissue 
[19]
 . There are two types of DM caused by 
microsatellite expansions in two different genes. DM type 1 
(DM1) is produced by the repetition of a trinucleotide (CTG) 
reiteration in exon 15 in the 3’ untranslated region (UTR) of 
the DM protein kinase (DMPK) gene. Instead, DM (DM2) is 
caused to the expansion of a tetranucleotide (CCTG) repeat 
in intron 1 of the zinc finger protein 9 (ZNF9) gene 
[20]
. 
Given the data obtained in C2C12 cells and data dealing with 
the reduction in expression of cyclin D3 in DM1, we 
evaluated whether an alteration of PLCβ1 levels of could 
give rise to a correct differentiation in DM1 and DM2. The 
expression of PLCβ1 in myogenesis of DM cells 
significantly decreases. Overexpression of PLCβ1a and 
PLCβ1b in differentiated cells from control contributors and 
patients with DM1 or DM2 revealed that both isoforms were 
required for the correct expression of cyclin D3 and 
myogenin in this disease, as cyclin D3 levels increased only 
in differentiated cells from control participants, whereas in 
DM1 and DM2 cells the amount of cyclin D3 was reduced. 
In fact, the presence of a cluster of aberrant RNA in the 
nucleus can give rise to a delay of the correct event involved 
in translation. On the other hand, also cyclin D3 was low in 
DM1 differentiating cells, and this could be a crucial state 
acting to compromise myoblast fusion, as cyclin D3 plays a 
critical role in the Myo-D-mediated arrest of the cell cycle 
preceding myoblast differentiation 
[17]
. These results 
furthermore emphasize that the PLCβ1 expression level is 
crucial in myoblast differentiation, acting as a positive 
regulator in the correction of compromised differentiation of 
skeletal muscle in DM human myoblasts. Very recently it has 
been demonstrated that a modulated expression of PLCβ1 
into mithramycin (MTH) treated K562 cells is able to modify 
miR-210 profile expression. The DNA binding drug MTH is 
a potent inducer of γ-globin mRNA and fetal hemoglobin 
accumulation in erythroid cells from healthy human subjects 
and β-thalassemia patients 
[21]
. miRNAs regulate a variety of 
cell functions such as cell proliferation, development, 
apoptosis, differentiation, and carcinogenesis 
[22,23]
. They can 
control several cancer-relevant processes such as migration 
and invasion 
[24]
. Recent studies also show that miRNAs play 
a key role in stem cell differentiation 
[25]
. They can control 
the genesis of cancer stem cells (CSCs) 
[26,27]
 and the 
achievement of the epithelial–mesenchymal transition (EMT) 
phenotype, 
[28]
 in that they are fundamentally connected with 
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drug resistance. MicroRNAs can target up to several hundred 
mRNAs, which makes them very powerful regulators and an 
aberrant miRNA expression can influence a multitude of cell 
signaling pathways. Hundreds of studies lead to the 
realization that miRNA profiles can diversify between 
normal and pathologiacl tissue, characterize tissues of origin 
and discriminate distinct subtypes of a specific type of cancer 
or even particular oncogenic abnormalities 
[29]
. Furthermore, 
miRNAs are important indicators for drug resistance, as the 
expression of miRNAs in chemoresistent cancer cells often 
differs from that in their parental chemosensitive cells 
[30]
. 
Recent studies found a different expression of circulating 
miRNAs in the serum of cancer patients 
[31,32]
. These findings 
highlight the importance of these small molecules as 
potential clinical biomarkers for diagnostic, predictive and 
prognostic purposes. Finally, current studies moved toward 
the application of microRNAs in cancer therapy as a new 
approach to interfere with the molecular mechanism of 
malignancies 
[33]
. Deregulation of miRNA expression results 
in haematological malignancies 
[34]
. A single miRNA targets 
many genes and it is not clear whether targeting a single gene 
or multiple genes leads to hematological malignancies. 
MiRNAs can function through several pathways which are 
involved in disease manifestations. Gain of function and loss 
of function experiments could give a better idea about the 
clinical use of miRNAs. In particular,  the miR-210 is 
related with the high expression level of fetal γ-globin in  
K562 cells treated with mithramycin 
[35,36]
. Moreover, 
miR-210 levels were elevated during mouse fetal liver 
erythroid cell differentiation in vitro 
[37]
. MiR-210 is a 
predominant miRNA induced under hypoxic condition in 
several types of cancers, and has contributed to cellular 
adaptation to hypoxic environment 
[38]
. It is known that 
miR-210 levels were elevated during mouse fetal liver 
erythroid cell differentiation in vitro 
[37]
. Novel data suggest a 
novel role for PLCβ1 in regulating miR-210 and  hint at the 
fact that, in human K562 erythroleukemia cells, the 
modulation of PLCβ1 expression is able to exert an 
impairment of normal erythropoiesis as assessed by γ-globin 
expression 
[39]
. PLCβ1 protein and mRNA content decreased 
in MTH-treated K562 cells in parallel with the induction of 
the differentiation process. Whilst PLCβ1 overexpression 
inhibits differentiation of the erythroid lineage K562 cell 
line, knockdown of PLCβ1 causes a significant up-regulation 
of γ-globin expression. To investigate the PLCβ1 effect on 
miRNA-210 expression after MTH treatment, experiments 
were performed in wild type K562 cells, in cells in which the 
PLCβ1 was overexpressed and in cells in which PLCβ1 was 
knocked-down. In proliferating K562, cells transfected with 
PLCβ1 show no significant difference in the level of 
miR-210 compared to vector transfected cells. On the other 
hand, K562 cells silenced for the expression of the PLCβ1 
show an increase of miR-210 levels. PLCβ1 overexpression 
led to a loss of induction of miR-210 expression after MTH 
treatment. Moreover, K562 cells silencing for the expression 
of the PLCβ1 induces an increase of miR-210 levels. 
Enhanced PLCβ1 level and reduced miR-210 level 
accompanies erythroid differentiation. This suggest that the 
role of PLCβ1 during erythropoiesis is linked to that of 
miR-210. Furthermore, transfection of K562 cells with 
anti-miR-210 caused a significant down-regulation of 
miR-210 expression and determination of γ-globin in the 
presence of anti-miR-210 showed a limited but appreciable 
reduction of γ-globin mRNA levels under the MTH 
treatment, suggesting that PLCβ1 signaling is implicated in 
the erythroid differentiation event. PLCβ1 can regulate 
miR-210 levels through PKCα signaling pathway. PKCα 
levels decreased in cells where PLCβ1 was overexpressed 
and silencing PKCα by RNAi technique, leads to a decrease 
in miR-210 and γ-globin expression levels as well as to a 
severe slowdown of cell differentiation in K562 cells. 
Understanding new PLCβ1 molecular targets, different from 
proteins, such as miRNA could result to new signaling 
pathway in physiology and pathology (and aberrant 
expression of miRNAs may contribute to abnormal 
erythropoiesis). In tumor tissues such as breast cancer and 
head and neck cancers, miR-210 expression levels have been 
demonstrated to be correlated with hypoxia gene signatures, 
which suggested a direct connection between miR-210 
expression and hypoxia. However, paradoxically opposing 
results were documented with regard to whether miR-210 is 
an oncogene or a tumor suppressor, and whether it is a 
positive or negative prognostic biomarker 
[40]
. PLCβ1 has 
been connected with several human diseases such as 
leukemia 
[41]
 and Alzheimer’s disease 
[42]
. It is notable that 
losses of PLCβ1 are found in patients with neurological 
disorders such as epileptic encephalopathiess and 
schizophrenia which are recapitulated in Knock-out mice 
[43,44]
. PLCβ1and G protein signaling are linked to gene 
regulation. PLCβ1 can affect the siRNA activity of genes for 
two metabolic enzymes, GAPDH and LDH, through its 
interaction with TRAX 
[45]
. The studies here suggest that 
genes whose levels are regulated by microRNAs with 
structures allowing rapid hydrolysis by C3PO are vulnerable 
to secondary regulation by cytosolic levels of PLC. These 
results show that the level of PLCβ1 affects the cellular 
amount of small RNAs and that it can reverse the siRNA 
activity of two cellular proteins involved in metabolism. It 
has been demonstrated that PLCβ1 reduces the nuclease 
activity of C3PO and TRAX by an amount that depends on 
RNA sequence and structure. Changes in microRNAs 
(miRNAs) occurs with PLCβ expression and some miRNAs 
are significantly down-regulated when PLCβ1 is 
over-expressed in HEK29 cells are closely linked to various 
leukemias and lymphomas in that PLCβ1 expression is 
directly linked to these diseases 
[45,46]
. A group of researchers 
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identified PLCβ1 as a, expected, conserved target of 
miR-26b 
[47]
. Cardiac hypertrophy is characterized by an 
upregulation of the transcription factor GATA4. GATA4 
appears to have a fundamental action in myocyte growth and 
survival. Amplification of miR-26b expression decreased 
GATA4-dependent transcription, endothelin-induced 
hypertrophy, and made susceptible the cells to apoptosis. 
Moreover, miR-26b targeted PLCβ1, which, successively, 
prevent miR-26b expression increase, producing a 
double-negative feedback loop. Resultantly, overexpression 
of miR-26b in the heart prevented up-regulation of its targets 
and the improvement of hypertrophy. Nonetheless, 
knockdown of miR-26b is not enough adequate for 
promoting hypertrophy. More recently, we demonstrated that 
lipid signaling could be involved in the regulation of cyclin 
D3 and, in turn, of cell proliferation in human 
erythroleukemia cells, K562. Indeed, we observed that 
overexpression of PLCβ1 drove to an up-modulation of 
cyclin D3 and a down-regulation of PKCα expression 
[48]
. 
This was followed by an accumulation of cells at G1/S 
transition. In particular, silencing of PKCα led to a very 
similar up-regulation of cyclin D3 compared to PLCβ1 
overexpression 
[48]
. PLCβ1 expression levels and cellular 
localization are necessary for the induction of erythroid 
differentiation. Nuclear PLCβ1 is down-regulated when 
Friend erythroleukemia cells treated with dimethysulfoxide 
differentiate and synthesize γ-globin. It was previously 
demonstrated that cyclin D3/cdk4 is a target of nuclear 
PLCβ1 signaling, which is able to activate cyclin D3 
promoter transcription during differentiation 
[1,11,14,15]
. 
Recently, it was shown a functional role for PLCβ1 in 
erythroleukemia K562 cells. More detailed investigations 
identified PLCβ1 targets and nuclear regulating molecules 
after the anticancer drug kinamycin F administration. 
Kinamycin F has been recently outlined as a powerful 
differentiating inducer of human erythroleukemia cells 
[49]
. 
We explored the impact of the antibiotic kinamycin F on  
PLCβ1 expression and  downstream targets of the its 
nuclear signal transduction pathway through an amplification  
or a withdrawal of the expression of both PLCβ1a and -β1b 
[50]
. The results showed that whilst the levels of PLCβ1a 
decreases upon differentiation, the levels of PLCβ1b do not, 
consequently the action of the drug is primarily direct 
towards the expression of PLCβ1a. These data underline that 
kinamycin F acts preferentially on PLCβ1a protein and 
mRNA expression levels.  PLCβ1a overexpression in K562 
cells did not affect γ-globin expression after kinamycin F 
treatment, implying a delay in erythroid differentiation, 
whereas amplification of PLCβ1b expression significantly 
increased the amount of the erythroid marker. Generally the 
expression of cyclin D3 in wild type cells decreases but only 
the overxpression of the PLCβ1a and not that of PLCβ1b is 
able to produce high levels of cyclin D3 expression even 
after the cells have been exposed to the drug.  The 
amplification of PLCβ1a expression is able to support the 
proliferative state of the cells and to the contrary, the 
expression of PLCβ1b already in itself favours the 
proceeding to differentiation. It is shown that the conflicting 
function of the two isozymes in the kinamycin F induced 
differentiation process occurs for their different topography 
within the cell since PLCβ1b has a significant higher 
expression restricted to the nuclear compartment as 
compared to PLCβ1a. Moreover it has been demonstrated 
that cells overexpressing PLCβ1a have a protective effect 
toward the process of apoptosis as assessed by flow 
cytometric analysis of Annexin V. Ultimately PLCβ1a and 
PLCβ1b are crucial regulators of erythropoiesis, having 
opposite action by means of a positive or a negative role in 
erythroid development, on the basis of their intracellular 
location. PLCβ1 has been studied also in the pancreatic β 
cells to find out if it had a role in the pathology of diabetes. 
In pancreatic MIN6 cells, PLCβ1 and PLC4 are isoforms 
localized in the nucleus and in the cytoplasm. The 
advancement of siRNA silencing technology offered the 
opportunity to evaluate the specific contribution of these two 
distinct PLC isoforms to insulin release and to distinguish 
between the effects of nuclear and cytoplasmic isoforms. In 
fact, they all affected glucose-induced insulin release in that 
by silencing each of them, it was consistently observed an 
inhibition of insulin release. Actually, nuclear PLCβ1 and 
PLC4 affected insulin secretion by regulating the expression 
of PPARγ and its responsive elements. The results identify a 
nuclear role for PLC in insulin secretion and adds PPARγ to 
the list of recognized molecular targets of nuclear PLCs 
[51]
. 
PLCβ1 expression levels could be increased by the presence 
of α-synuclein through improvement from enzymes 
degradation such as μ-calpain. α-synuclein is a conserved 
protein that is a fundamental element in neurodegenerative 
plaques and mutations are correlated with infrequent forms 
of familial Parkinson’s disease. The level of expression of 
α-synuclein increases the presence of PLCβ1 and this 
balance does not appear to be determined to alteration in 
transcription or in ubitquitin-mediated degradation 
[52]
. While 
PLCβ1 and other α-synuclein binding partners could stabilize 
α-synuclein structure, it is possible that their absence or their 
interaction promotes α-synuclein aggregation and 
consequential pathogenesis. These results highlight the 
concept that by changing the cellular expression of specific 
enzymes, α-synuclein might improve PLCβ1 signaling 
pathways and events within the cells. Abnormal expression 
patterns of PLCβ1 in specific brain areas of patients with 
schizophrenia, and its high genetic linkage to the disorder 
implicated a pathogenetical involvement of PLCβ1 signaling 
system. In fact, PLCβ1 is expressed in select areas of brain 
such as cerebral cortex, hippocampus, amygdala, lateral 
septum, and olfactory bulb 
[53]
, and, therefore, is implicated 
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for participations in diverse critical functions related to 
forebrain diseases such as schizophrenia 
[54]
. 
Thus, dysregulation of phospholipases contributes to a 
number of human diseases and primary PLCβ1 have been 
identified as therapeutic targets for prevention and treatment 
of diseases. The data reviewed here show that PLCβ1 
signaling has a physiological and pathological role that is 
still not fully understood. More specific studies in the future, 
processed in terms of physiological conditions and in 
diseases, will increase knowledge about new PLCβ1 
molecular targets and could give outcome to novel, original 
and unforeseen discoveries that are crucial for comprising the 
function and the importance of this pathway in physiology 
and in pathology. 
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